2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents

Details for Australian Patent Application No. 2006319248 (hide)

Owner F. Hoffmann-La Roche AG

Inventors So, Sung-Sau; Ding, Qingjie; Pizzolato, Giacomo; Kong, Norman; Vu, Binh Thanh; Roberts, John Lawson; Graves, Bradford James; Lovey, Allen John; Liu, Jin-Jun; Wovkulich, Peter Michael

Agent Davies Collison Cave

Pub. Number AU-B-2006319248

PCT Pub. Number WO2007/063013

Priority 60/741,223 01.12.05 US; 60/852,747 19.10.06 US

Filing date 22 November 2006

Wipo publication date 7 June 2007

Acceptance publication date 27 September 2012

International Classifications

C07D 233/22 Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

A61K 31/4164 - 1,3-Diazoles

A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 35/00 Antineoplastic agents

C07D 233/26 Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 401/06 Heterocyclic compounds containing two or more hetero rings

C07D 403/06 Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 407/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

C07D 409/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 487/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

5 June 2008 PCT application entered the National Phase

  PCT publication WO2007/063013 Priority application(s): WO2007/063013

27 September 2012 Application Accepted

  Published as AU-B-2006319248

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006319259-Keratin-binding effector molecules containing reactive dyes

2006319247-Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors